BioAge Labs Raises $170m to Develop Therapies Using AI

BioAge Labs Raises $170m to Develop Therapies Using AI Bloomberg Technology BioAge Labs, a clinical-stage biotechnology company developing therapies for obesity and metabolic disease thanks to their AI-powered discovery platform, raised $170 million in an oversubscribed series D financing round led by Sofinnova Investments. Kristen Fortney, BioAge CEO and Co-Founder, joins Ed Ludlow and Caroline Hyde on "Bloomberg Technology."
--------
Like this video? Subscribe to Bloomberg Technology on YouTube:
https://www.youtube.com/channel/UCrM7B7SL_g1edFOnmj-SDKg
Watch the latest full episodes of "Bloomberg Technology" with Caroline Hyde and Ed Ludlow here: https://tinyurl.com/ycyevxda

Get the latest in tech from Silicon Valley and around the world here:
https://www.bloomberg.com/technology

Connect with us on...
Twitter: https://twitter.com/technology
Facebook: https://www.facebook.com/BloombergTechnology
Instagram: https://www.instagram.com/bloombergbusiness/